- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01136746
Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (HMH)
November 7, 2012 updated by: Eli Lilly and Company
Randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients Without Known History of Diabetes: The HMH Trial
The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This study involves a comparison of 2 methods for administering subcutaneous insulin therapy to non-critically ill adult patients with hyperglycemia and without known history of diabetes who are admitted to non-intensive care unit (ICU) general medical hospital services.
Basal-bolus therapy, considered the gold standard for glucose control in patients with known diabetes, will be compared with sliding scale insulin, a commonly used method of glucose control (prevailing standard practice) in hospitalized patients.
In this study, basal-bolus therapy will consist of once-daily glargine plus lispro 3 to 4 times daily adjusted to achieve pre-meal capillary plasma glucose <140 milligrams per deciliter (mg/dL) and bedtime capillary plasma glucose <180 mg/dL for patients who are eating [predose plasma glucose <140 mg/dL for patients with nil per os (NPO) orders]; sliding scale insulin will be administered using human regular insulin 4 times daily as needed adjusted to achieve predose capillary plasma glucose target <140 mg/dL in patients who are eating or have NPO orders.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Florida
-
Jacksonville, Florida, United States, 32209
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Miami, Florida, United States, 33136
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Weston, Florida, United States, 33331
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Georgia
-
Atlanta, Georgia, United States, 30312
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Kansas
-
Topeka, Kansas, United States, 66604
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Kentucky
-
Hazard, Kentucky, United States, 41701
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Maine
-
Bangor, Maine, United States, 04401
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Major Inclusion Criteria:
- No known history of diabetes
- Admission or pre-entry plasma glucose (PG) level between 140 and 400 mg/dL
- Non-critically ill and admitted to acute care medical services
- Have a body mass index greater than or equal to 18.5 kg/m^2 and less than or equal to 45 kilograms per square meter (kg/m^2)
Major Exclusion Criteria:
- Received any insulin/analog therapy for longer than 108 hours prior to study entry or intermediate- or long-acting insulin/analogs (neutral protamine Hagedorn, detemir, or glargine) in the 24 hours prior to randomization or any intravenous insulin therapy prior to randomization
- Laboratory evidence of diabetic ketoacidosis for patients with pre-randomization PG greater than 250 mg/dL
- Have taken any oral or injectable antihyperglycemic medications other than insulin within 3 months prior to study entry
- Have acute critical illness or are expected to require admission to an ICU or equivalent or be treated with glucocorticoid therapy during the hospital study period
- Expected hospitalization less than 24 hours post-randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Sliding scale regular insulin
|
Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
Other Names:
|
EXPERIMENTAL: Basal-bolus therapy
|
Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
Other Names:
Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Plasma Glucose (MPG) Throughout Hospital Study Period
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Overall MPG is derived as the mean of plasma glucose (PG) readings from Day/Visit 1 to Day/Visit 10.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Results are reported as the percentage of total number of capillary plasma glucose measurements within the range of 71 to 179 mg/dL for each treatment arm.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Plasma Glucose (MPG) by Hospital Day
Time Frame: Day 1 up to day 7 of hospital study period
|
The intent was to report results up to Day 10; however, due to low enrollment, mean and standard deviations are only reported up to Day 7.
|
Day 1 up to day 7 of hospital study period
|
Percentage of Plasma Glucose Measurements Within Range 71 to 179 mg/dL by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL Throughout Hospital Study Period
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Mean Fasting Plasma Glucose (FPG) by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Mean FPG Throughout Hospital Study Period
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL Throughout the Hospital Study Period
Time Frame: Throughout the hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout the hospital study period (1 to 10 days post-randomization)
|
Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL Throughout the Hospital Study Period
Time Frame: Throughout the hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout the hospital study period (1 to 10 days post-randomization)
|
Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Percentage of Capillary PG Measurements >240 mg/dL Throughout the Hospital Study Period
Time Frame: Throughout the hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout the hospital study period (1 to 10 days post-randomization)
|
Percentage of Capillary PG Measurements >240 mg/dL by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Total Daily Dose (TDD) of Insulin (Units) Throughout the Hospital Study Period
Time Frame: Throughout the hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout the hospital study period (1 to 10 days post-randomization)
|
TDD of Insulin (Units/kg) Throughout the Hospital Study Period
Time Frame: Throughout the hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout the hospital study period (1 to 10 days post-randomization)
|
TDD of Insulin (Units) by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
TDD of Insulin (Units/kg) by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Length of Hospital Stay Post-randomization Throughout the Hospital Study Period
Time Frame: Throughout the hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout the hospital study period (1 to 10 days post-randomization)
|
Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010).
Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG <40 mg/dL (Umpierrez et al. 2007; Moghissi et al. 2009; Umpierrez et al. 2009), even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), Throughout Hospital Study Period
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010).
Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG <40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010).
Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG <40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), by Hospital Day
Time Frame: Day 1 up to day 10 of hospital study period
|
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010).
Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG <40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.
Due to low enrollment, this outcome measure was not analyzed.
|
Day 1 up to day 10 of hospital study period
|
Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Treatment-emergent adverse event - any untoward medical occurrence that either occurred or worsened at any time after treatment baseline and which did not necessarily have a causal relationship with this treatment.
A summary of adverse events is located in the Reported Adverse Event Module.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Percentage of Participants Requiring Intensive Care Unit Transfer
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Percentage of Participants With Deterioration of Renal Function Throughout the Hospital Study Period
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Deterioration of renal function was defined by an increase in serum creatinine by >0.5 milligrams per deciliter (mg/dL).
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Percentage of Participants With Documented Nosocomial Infections
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Number of Participants With Major Adverse Cardiovascular Events (MACE)
Time Frame: Throughout hospital study period (1 to 10 days post-randomization)
|
MACE was defined as the composite of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke.
Due to low enrollment, this outcome measure was not analyzed.
|
Throughout hospital study period (1 to 10 days post-randomization)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005 May;28(5):1245-9. doi: 10.2337/diacare.28.5.1245. No abstract available.
- American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010 Jan;33 Suppl 1(Suppl 1):S11-61. doi: 10.2337/dc10-S011. No abstract available. Erratum In: Diabetes Care. 2010 Mar;33(3):692.
- Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009 May-Jun;15(4):353-69. doi: 10.4158/EP09102.RA. No abstract available.
- Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007 Sep;30(9):2181-6. doi: 10.2337/dc07-0295. Epub 2007 May 18.
- Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, Munoz C, Newton C, Peng L, Baldwin D. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009 Feb;94(2):564-9. doi: 10.1210/jc.2008-1441. Epub 2008 Nov 18.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (ACTUAL)
November 1, 2011
Study Completion (ACTUAL)
November 1, 2011
Study Registration Dates
First Submitted
June 2, 2010
First Submitted That Met QC Criteria
June 2, 2010
First Posted (ESTIMATE)
June 3, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
November 13, 2012
Last Update Submitted That Met QC Criteria
November 7, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13698
- F3Z-US-IOPZ (OTHER: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
Mayo ClinicCompletedHospital Hyperglycemia | Post-transplant HyperglycemiaUnited States
-
Zealand University HospitalNot yet recruitingStress Hyperglycemia | Postoperative Hyperglycemia
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...RecruitingHyperglycemia StressUnited States
-
Loughborough UniversityUniversity of BedfordshireCompletedPostprandial HyperglycemiaUnited Kingdom
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaCompleted
-
Medical University of ViennaCompleted
-
Addis Ababa UniversityCompletedHyperglycemia, Postprandial
-
University of Eastern FinlandFinnsugar LtdCompletedHyperglycemia, PostprandialFinland
Clinical Trials on Human regular insulin
-
Eli Lilly and CompanyInsulet CorporationCompletedType 2 Diabetes MellitusUnited States, Puerto Rico
-
PfizerTerminatedDiabetes MellitusUnited States
-
Brown UniversityRecruiting
-
Mannkind CorporationCompleted
-
University of Sao PauloCompletedHeart Valve Diseases | Ventricular Dysfunction | Hyperglycaemia During Perioperative PeriodBrazil
-
Vanderbilt UniversityWithdrawn
-
WockhardtCompletedDiabetes MellitusUnited States
-
Halozyme TherapeuticsCompleted